PODD Stock Price Today (October 2026) — Insulet Corporation Analysis & Key Metrics 2026-10-07
Insulet Corporation (PODD) is trading at $134.36, down 0.27% today (as of October 2026). The stock continues to show pressure below major moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $171.91 (27.9% upside).
- Volatility is low (17.28% annualized), implying relatively contained price movements for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (23.50% YoY) alongside competitive pressures in the Medical Devices space.
PODD Stock Analysis: Key Metrics & Valuation (October 2026)
Concise, actionable data for investors
Insulet Corporation - Historical Price & Volume
- Price
- Volume
- Latest price
Market Cap
Enterprise Value: $9.73B
P/E Ratio
Forward P/E: 19.28
Revenue Growth
Year over Year
Analyst Target
+27.9% upside potential
Key Investor Questions About PODD
What investors need to know before buying
Based on current market data, PODD presents a neutral technical setup with looking solid fundamentals.
- Technicals say: Neutral (RSI 43.88)
- Fundamentals say: Looking solid (debt and growth supportive)
PODD's growth trajectory depends on its ability to expand within the Medical Devices sector while managing margin pressures.
- Future growth will depend on performance in core Medical Devices operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for PODD investors include debt exposure and competitive dynamics in the Medical Devices industry.
- $948.40M in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Medical Devices.
52-Week Trading Range
Over the past year, PODD stock traded between $126.40 and $354.88 and currently trades near the low end of that range. Big swings are less likely unless a major catalyst emerges.
Volatility & Risk Profile
With 17.28% annualized volatility and β=0.33, the stock exhibits low sensitivity to market moves—making PODD suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
Lower institutional support combined with high short selling points to negative sentiment.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Insulet (PODD) Stock May Trade At A Discount To Fair Value
Insulet has seen its share price fall hard over the past year, which puts the focus squarely on whether the current market value still lines up with the cash the business is expected to generate. With the stock under pressure, the key issue now is how its cash flows compare with the price investors are paying today. Over the past 12 months, Insulet shares have declined 57.2%. This puts a lot of weight on whether the business can support the present valuation through its future cash...
Insulet (PODD) Reworked Its Debt, Is The Stock Still Cheap?
Insulet (PODD) recently reworked its financing by replacing $475 million of term loans with new debt at lower interest margins and expanding its revolving credit facility, a move that directly reshapes the balance sheet. Insulet’s refinancing lands after a tough stretch for the stock, with the share price down 52% year to date and the 1 year total shareholder return declining 58%. This points to fading momentum even before its recent index removal and conference appearances. Scan beyond...
Insulet Targets Type 2 Retention as Omnipod 6 and Global Growth Gain Momentum
Insulet (NASDAQ:PODD) Chief Operating Officer Eric Benjamin said the company remains focused on expanding adoption of automated insulin delivery, or AID, systems across large and underpenetrated diabetes markets, while addressing elevated early attrition among certain Type 2 diabetes customers. Spe
How Is Insulet's Stock Performance Compared to Other Medical Devices Stocks?
Insulet has notably underperformed the Medical Devices industry over the past year, but analysts are cautiously optimistic about the stock’s prospects.
BCSM Exits Insulet Corporation (PODD), Maintains Watchlist Status
Baron Capital, an investment management company, released its second-quarter 2026 investor letter for its “Baron SMID Cap ETF”. You can download the letter here. Baron SMID Cap ETF® (BCSM) gained 15.62% (NAV) in the second quarter, underperforming the Russell 2500 Growth Index’s 24.02% return. The trend towards “AI winners” continued, focusing on companies related to chips, […]
2 S&P 500 Stocks with Impressive Fundamentals and 1 We Turn Down
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth, heavy debt, or disruptive new competitors.
Why Pay More For Stryker When BSX Stock Is On Sale?
A medical device giant now costs more than its faster-growing rivals, forcing investors to decide if its premium price tag is buying durable quality or just yesterday's story.
Beta Bionics’ insulin patch pump gets FDA nod
By bringing its first patch pump to market, Beta Bionics will be able to compete with industry leader Insulet.
Is it Prudent to Retain Insulet Stock in Your Portfolio for Now?
PODD's Omnipod 5 adoption, product expansion and raised international growth outlook support its growth prospects despite competitive and cost pressures.
Artisan Sold Insulet (PODD) Due to Competition Concerns
Artisan Partners, an investment management company, released its second-quarter 2026 investor letter for the “Artisan Mid Cap Fund”. The letter can be downloaded here. Global equities rebounded sharply in Q2 2026, recovering from March lows as resilient economic data, strong corporate earnings, and continued AI investment improved investor sentiment despite inflation concerns, delayed rate cuts, and […]
Explore More Analysis for PODD
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Earnings snapshot
Next report Nov 4, 2026
Frequently Asked Questions
Common investor questions about Insulet Corporation
Insulet Corporation (PODD) is currently trading at $134.36. The RSI (14-day) is at 43.9, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $171.91 implies 27.9% upside from current levels. Volatility is low at 17.3% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Insulet Corporation (PODD): The trailing P/E ratio is 25.85, which is in line with broader market averages. The forward P/E is 19.28, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 1.44, near 1.0, suggesting roughly fair value relative to growth. Price-to-Book is 6.72. Price-to-Sales is 3.13. Valuation should be compared to Medical Devices industry peers for context, as different sectors trade at different multiples.
Based on 22 analysts covering PODD, the consensus price target is $171.91. This represents a 27.9% upside from the current price of $134.36. The range spans from a low target of $144.00 to a high target of $275.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Insulet Corporation (PODD) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Insulet Corporation (PODD) investors include: 1. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 2. Medical Devices sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Insulet Corporation's (PODD) current debt and financial health profile: Total debt stands at $948.40M. The debt-to-equity ratio is 0.67x, which is moderate and generally manageable for most companies. The current ratio is 2.49, indicating strong short-term liquidity. The quick ratio is 1.51. The company holds $534.90M in cash and equivalents. Free cash flow is positive at $236.90M, providing a cushion for debt servicing and shareholder returns.